1. Home
  2. GAIN vs TRML Comparison

GAIN vs TRML Comparison

Compare GAIN & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAIN
  • TRML
  • Stock Information
  • Founded
  • GAIN 2005
  • TRML 2021
  • Country
  • GAIN United States
  • TRML United States
  • Employees
  • GAIN N/A
  • TRML N/A
  • Industry
  • GAIN Finance: Consumer Services
  • TRML Biotechnology: Pharmaceutical Preparations
  • Sector
  • GAIN Finance
  • TRML Health Care
  • Exchange
  • GAIN Nasdaq
  • TRML Nasdaq
  • Market Cap
  • GAIN 497.3M
  • TRML 509.8M
  • IPO Year
  • GAIN 2005
  • TRML N/A
  • Fundamental
  • Price
  • GAIN $13.39
  • TRML $15.21
  • Analyst Decision
  • GAIN Hold
  • TRML Strong Buy
  • Analyst Count
  • GAIN 2
  • TRML 6
  • Target Price
  • GAIN $13.75
  • TRML $45.20
  • AVG Volume (30 Days)
  • GAIN 114.8K
  • TRML 356.2K
  • Earning Date
  • GAIN 05-07-2025
  • TRML 03-13-2025
  • Dividend Yield
  • GAIN 7.18%
  • TRML N/A
  • EPS Growth
  • GAIN N/A
  • TRML N/A
  • EPS
  • GAIN 1.92
  • TRML N/A
  • Revenue
  • GAIN $89,176,000.00
  • TRML N/A
  • Revenue This Year
  • GAIN $5.92
  • TRML $363.93
  • Revenue Next Year
  • GAIN $10.25
  • TRML N/A
  • P/E Ratio
  • GAIN $7.10
  • TRML N/A
  • Revenue Growth
  • GAIN 6.78
  • TRML N/A
  • 52 Week Low
  • GAIN $12.46
  • TRML $11.87
  • 52 Week High
  • GAIN $14.85
  • TRML $29.79
  • Technical
  • Relative Strength Index (RSI)
  • GAIN 47.29
  • TRML 44.57
  • Support Level
  • GAIN $13.52
  • TRML $16.39
  • Resistance Level
  • GAIN $13.68
  • TRML $17.36
  • Average True Range (ATR)
  • GAIN 0.18
  • TRML 1.03
  • MACD
  • GAIN 0.01
  • TRML -0.09
  • Stochastic Oscillator
  • GAIN 53.28
  • TRML 8.54

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

About TRML Tourmaline Bio Inc.

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

Share on Social Networks: